CLASSIC HODGKIN LYMPHOMA
Clinical trials for CLASSIC HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new CLASSIC HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for CLASSIC HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Lymphoma drug combo trial halted early
Disease control TerminatedThis study tested a combination of two drugs, isatuximab and cemiplimab, in people with certain types of lymphoma that had come back or not responded to treatment. The goal was to see if the combination was safe and could shrink tumors. The trial was stopped early, so results are…
Matched conditions: CLASSIC HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 22, 2026 12:08 UTC
-
Experimental lymphoma drug combo shows promise in early trial
Disease control TerminatedThis study tested a new drug called SAR444245, alone or with pembrolizumab, in 14 people aged 12 and older with B cell lymphoma that came back or didn't respond to treatment. The goal was to see if the drug could shrink tumors. The study was terminated early, so results are limit…
Matched conditions: CLASSIC HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 11, 2026 11:57 UTC